It was a calm week for drug review and approvals.
Indeed, one of the biggest news stories is about something that won't happen: US FDA advisory committee review of Neurocrine Biosciences Inc.'s Ingrezza (valbenazine) for tardive dyskinesia. The company interprets FDA's cancellation of the Feb. 16, 2017, meeting as a positive sign for approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?